Compare Amgen, Inc. (AMGN) vs SAP SE (SAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs SAP SE — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while SAP SE trades at $158.18 (market cap $182.93B). The key difference: Amgen, Inc. and SAP SE are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SAP | |
|---|---|---|
Market Cap | $196.12B | $182.93B |
Sector | Health | Technology |
52-Week High | $388.16 | $308.61 |
52-Week Low | $271.18 | $148.06 |
Enterprise Value | $241.41B | $180.44B |
Dividend Yield | 2.77% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SAP trades at $157.86, down 0.38% on the day, amid a bearish technical signal but strong fundamental performance. The stock has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $2.05. Revenue grew to $36.80B in 2025, with a net income margin of 19.58%, while the company maintains robust cash flow from operations of $9.16B. Recent news highlights SAP's resolution of EU antitrust concerns and strategic focus on AI investments to drive future growth.
The outlook for SAP is positive based on solid fundamentals and analyst consensus, with a price target of $228.50 implying significant upside. However, risks include competitive pressures, execution of AI initiatives, and macroeconomic volatility. Investors should weigh the strong profitability and growth trajectory against near-term technical weakness and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
